Polyethyleneglycol3350 vs Tegaserod in Treatment of Patients With Chronic Constipation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Alabama
-
Mobile, Alabama, United States, 36693
-
-
Arizona
-
Glendale, Arizona, United States, 85306
-
-
California
-
Anaheim, California, United States, 92801
-
Sacramento, California, United States, 95825
-
San Diego, California, United States, 92103
-
-
Florida
-
Lake Worth, Florida, United States, 33461
-
Largo, Florida, United States, 33770
-
St. Petersburg, Florida, United States, 33707
-
-
Maryland
-
Laurel, Maryland, United States, 20707
-
-
Massachusetts
-
Brighton, Massachusetts, United States, 02135
-
-
Missouri
-
St. Louis, Missouri, United States, 63017
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27609
-
Raleigh, North Carolina, United States, 27612
-
Winston-Salem, North Carolina, United States, 27103
-
-
Ohio
-
Cincinnati, Ohio, United States, 45236
-
-
South Carolina
-
Greer, South Carolina, United States, 29651
-
-
Tennessee
-
Memphis, Tennessee, United States, 38120
-
-
Texas
-
Austin, Texas, United States, 78705
-
Dallas, Texas, United States, 75234
-
Fort Worth, Texas, United States, 76135
-
San Angelo, Texas, United States, 76904
-
-
Utah
-
Salt Lake City, Utah, United States, 84121
-
-
Virginia
-
Newport News, Virginia, United States, 23606
-
Norfolk, Virginia, United States, 23502
-
Richmond, Virginia, United States, 23294
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female outpatients at least 18 years of age
- Constipated according to ROME I criteria
- If female and of childbearing potential, patient must be surgically sterilized or using oral contraceptives, depot contraceptives, double- barrier method, intrauterine device, or testifies that she is monogamous with a vasectomized partner, or practices abstinence and will continue to do so during the duration of study
- Are otherwise in good health, as judged by a physical examination
- In the investigator's judgment, patient is mentally competent to sign an instrument of informed consent
Exclusion Criteria:
- Patients with heme positive stool at screening that is not associated with hemorrhoids or anal fissures.
- Patients with hypo- or hyperthyroidism as determined by medical history.
- Patients with severe renal impairment.
- Patients with moderate or severe hepatic impairment.
- Patients with known or suspected perforation or obstruction.
- History of gastric retention, inflammatory bowel disease, bowel resection, or colostomy.
- Patients with symptomatic gallbladder disease, suspected sphincter of Oddi dysfunction, or abdominal adhesions.
- Patients with a known history of organic cause for their constipation.
Patients currently taking, or planning to take any of the following medications that are known to effect bowel habits:
- Antidiarrheals
- Antacids containing magnesium or aluminum salts
- Anticholinergics
- Antispasmodic agents
- Erythromycin and other macrolides
- Octreotide
- Lotronex, Zofran, or other 5-HT3 antagonists
- Zelnorm, or other 5-HT4 agonists
- Opiods/narcotic analgesics
- Prokinetics
- Serotonin re-uptake inhibitors or tricyclic antidepressants
- Calcium antagonists
- Patients who are breastfeeding, pregnant, or intend to become pregnant during the study.
- Female patients of childbearing potential who refuse a pregnancy test.
- Patients with a known allergy to tegaserod (or any of its excipients) or polyethyleneglycol.
- Patients who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedures.
- Patients who, within the past 30 days have participated in an investigational clinical study.
- Patients that have undergone a colonoscopy within 30 days of screening
- Patients that are currently taking, or have previously been treated with polyethyleneglycol3350 or tegaserod.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
A successful outcome is defined as no longer meeting the definition of constipation using ROME I criteria
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Analysis of individual ROME I criteria
|
|
Safety (adverse event review)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jorge Herrera, MD, University of South Alabama
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 851-ZCC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.